logo
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
EN 简 繁
img img img
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us
QR
  • Board of Directors
  • Corporate Governance Information

Audit Committee

Mrs. Yvonne Law (Chairman)

Mr. Fengmao Hua

Mr. Mincong Huang

Remuneration Committee

Ms. Monin Ung (Chairman)

Dr. Xiaochang Dai

Dr. Cheung Hoi Yu

Nomination Committee

Mr. Fengmao Hua (Chairman)

Dr. Patrick Y. Lu

Dr. Cheung Hoi Yu

  • NOMINATION POLICY

    NOMINATION POLICY
  • LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS

    LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
  • TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE UNDER THE BOARD OF DIRECTORS

    TERMS OF REFERENCE OF THE REMUNERATION COMMITTEE UNDER THE BOARD OF DIRECTORS
  • TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS

    TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF DIRECTORS
  • TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF DIRECTORS

    TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF DIRECTORS
  • ARTICLES OF ASSOCIATION

    ARTICLES OF ASSOCIATION
logo
Sirnaomics Ltd.

401 Professional Dr, STE 280 Gaithersburg, MD 20879, USA

© 2007-2022 by Sirnaomics
  • About Us
    • Who We Are
    • Leadership Team
    • Our Story
    • Patent
    • Contact Us
  • Science & Pipeline
    • The Science of RNAi
    • Pipeline
      • Oncology
      • Fibrosis
      • Medical Aesthetic
      • Antiviral
      • GaINAc-RNAi triggers
    • Research & Development
    • Clinical Studies
    • Clinical Manufacturing
  • Investor Relations
    • Analyst Coverage
    • Information Disclosure
      • Announcements & Circulars
      • Financial Reports
      • Listing Documents
      • ESG Reports
    • Events & Presentations
    • Corporate Governance
    • Investor Enquiries
  • Partnership
    • Business Development
    • Our Partners
  • News
    • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics In The News
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • news
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Press Release
      • Sirnaomics Ltd. Listed on Main Board of HKEX
      • Sirnaomics Receives Safe to Proceed Letter for U.S. FDA Investigational New Drug Application for Systemic RNAi Therapeutic STP707 in Primary Sclerosing Cholangitis (PSC)
      • Sirnaomics Announces Interim Data from Phase II Clinical Trial of STP705 for Treatment of Cutaneous Basal Cell Carcinoma
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and Product Pipeline at the 2022 Oligonucleotide & Precision Therapeutics Congress
      • RNAimmune Secures $27 Million Series A Round of Financing for Development of mRNA Therapeutics and Vaccines
      • Sirnaomics Doses First Subject in Phase I Clinical Trial of STP707 for the Treatment of Liver Fibrosis in Primary Sclerosing Cholangitis
      • Sirnaomics Launches Phase I Clinical Trial of RNAi Therapeutic STP707 Delivered Systemically for the Treatment of Solid Tumors
      • Sirnaomics to Present Latest Developments on its GalNAc-Based Liver-Targeting Platforms and GalAhead™ Programs at the TIDES USA 2022  
      • Sirnaomics will present clinical study results and development strategy for Cancer RNA Therapeutics at the 2022 Pre-ASCO China Summit
    • Sirnaomics in the News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • Sirnaomics In The News
      • After a $50M IPO, Sirnaomics aims to market the first RNAi drug for oncology
      • Shortly after its latest mega-round, Sirnaomics CEO Patrick Lu says it's time to go public
    • Media Outreach
  • Careers
    • Working at Sirnaomics
    • Join Us